ContraFect to Present at 2nd International Symposium on Antimicrobial Hydrolytic Enzymes
01 nov. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 01, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Participate in World Antimicrobial Resistance Congress 2018
22 oct. 2018 17h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at the “Exploring the Antibiotic Pipeline 2018” Symposium and also to Present New Data on CF-301 (exebacase) at IDWeek 2018
25 sept. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 25, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at Two Upcoming Investor Conferences
20 sept. 2018 17h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia
06 sept. 2018 08h30 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 06, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at Two Upcoming Investor Conferences
29 août 2018 17h30 HE
|
ContraFect Corporation
YONKERS, N.Y., Aug. 29, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
22 août 2018 17h00 HE
|
ContraFect Corporation
YONKERS, New York, Aug. 22, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections
14 août 2018 17h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Aug. 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Announces Second Quarter 2018 Financial Results
09 août 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Corporation Prices $10 Million Public Offering of Common Stock
27 juil. 2018 09h00 HE
|
ContraFect Corporation
YONKERS, N.Y., July 27, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...